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ABSTRACT
Objectives: The use of magnesium sulfate (MgSO4)
in European obstetric units is unknown. We aimed to
describe reported policies and actual use of MgSO4 in
women delivering before 32 weeks of gestation by
indication.
Methods: We used data from the European Perinatal
Intensive Care in Europe (EPICE) population-based
cohort study of births before 32 weeks of gestation in
19 regions in 11 European countries. Data were
collected from April 2011 to September 2012 from
medical records and questionnaires. The study
population comprised 720 women with severe pre-
eclampsia, eclampsia or HELLP and 3658 without pre-
eclampsia delivering from 24 to 31 weeks of gestation
in 119 maternity units with 20 or more very preterm
deliveries per year.
Results: Among women with severe pre-eclampsia,
eclampsia or HELLP, 255 (35.4%) received MgSO4
before delivery. 41% of units reported use of MgSO4
whenever possible for pre-eclampsia and administered
MgSO4 more often than units reporting use
sometimes. In women without pre-eclampsia, 95
(2.6%) received MgSO4. 9 units (7.6%) reported using
MgSO4 for fetal neuroprotection whenever possible. In
these units, the median rate of MgSO4 use for
deliveries without severe pre-eclampsia, eclampsia and
HELLP was 14.3%. Only 1 unit reported using MgSO4
as a first-line tocolytic. Among women without pre-
eclampsia, MgSO4 use was not higher in women
hospitalised before delivery for preterm labour.
Conclusions: Severe pre-eclampsia, eclampsia or
HELLP are not treated with MgSO4 as frequently as
evidence-based medicine recommends. MgSO4 is
seldom used for fetal neuroprotection, and is no longer
used for tocolysis. To continuously lower morbidity,
greater attention to use of MgSO4 is needed.
INTRODUCTION
Magnesium sulfate (MgSO4) has long been
used in obstetric practice. Evidence supports
the use of MgSO4 as a ﬁrst-line treatment for
severe pre-eclampsia and eclampsia.1 Its pre-
vious use as a tocolytic is no longer
recommended as it was found to be ineffect-
ive in inhibiting preterm birth.2 Currently, it
is debated whether MgSO4 can also be used
to protect the immature fetal and neonatal
brain. Several meta-analyses found that
MgSO4, administered prior to preterm birth,
decreases risks of cerebral palsy.3–6 However,
some have suggested that additional data are
needed before accepting MgSO4 as an
evidence-based therapy for fetal neuropro-
tection.7 The biological mechanisms of
MgSO4 are unclear. Possible mechanisms
include an ability to decrease the levels of
proinﬂammatory cytokines8 9 and to dilate
fetal cerebral and umbilical arteries.10 11
National guidelines concerning administra-
tion of MgSO4 to prevent eclampsia are avail-
able in many European countries,12 and a
guideline is also available from the WHO.13
Only a few countries in Europe, however,
including Belgium, Ireland and the UK, have
guidelines on the use of MgSO4 for neuro-
protection.14–16 A Canadian study on the
actual use of MgSO4 was recently published,
17
Strengths and limitations of this study
▪ This is the first study to explore reported policies
of use of magnesium sulfate (MgSO4) and the
actual use in European obstetrical units by
indication.
▪ A major strength of the study is the multi-
national, prospective population-based sample
which includes deliveries in all public and private
maternity hospitals in 19 regions in 11 European
countries covering over 850 000 births annually
securing a high degree of generalisability.
▪ Another strength is the low risk of interobserver
variability between units due to pre-established
definitions of diagnoses and terms and pretested
questionnaires in all regions.
▪ Limitations include missing information for valid-
ation of severe pre-eclampsia as blood pres-
sures, urine samples and blood chemistry were
not collected.
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but except for a small, retrospective French single-centre
study,18 data on use of MgSO4 in Europe are lacking.
We aimed to explore reported policies of use of
MgSO4 and the actual use in European obstetrical units
by indication in women giving birth before 32 weeks of
gestation using data from a large population-based
multiregional cohort.
MATERIAL AND METHODS
Study design
This study is based on the analysis of data from the
European Perinatal Intensive Care in Europe (EPICE)
cohort.19 This is a population-based, prospective cohort
study of infants born at 22+0 weeks to 31+6 weeks of ges-
tation in 19 regions in 11 countries in Europe (Belgium,
Denmark, Estonia, France, Germany, Italy, the
Netherlands, Poland, Portugal, Sweden and the UK).
Data were collected on all births in each region
during varying 12-month periods between April 2011
and September 2012, with the exception of France
where the inclusion period lasted 6 months. Clinical
data were collected from medical records in 431 obstet-
ric and their associated neonatal units following a stan-
dardised protocol, established by a scientiﬁc committee
and pretested before data collecting began. Data were
cross-checked with maternity registers or other external
data sources.
In the spring of 2012, a unit questionnaire was also
sent by mail or email to department heads of obstetrical
and neonatal units caring for infants in the cohort.
Units with a neonatal department admitting at least 10
very preterm infants per year were included in this
study. The unit questionnaires collected information on
the structural characteristics and protocols and policies
related to the care of very preterm infants. The question-
naire was pretested outside of the study regions in all
countries.
Data and definitions
We used data from the cohort study on maternal, preg-
nancy and fetal characteristics including maternal age,
gestational age, intrauterine growth restriction (IUGR),
sex of the fetus, number of fetuses, parity, in utero trans-
fer, pregnancy complications, use of prenatal corticoster-
oids (at least one injection), caesarean section
(prelabour or after onset of labour), indication for the
caesarean section (fetal reasons, maternal reasons or
unit policy) and administration of MgSO4 before deliv-
ery (including timing of ﬁrst dose and total dose).
Gestational age was deﬁned as the attending obstetri-
cian’s best estimate based on last menstrual period,
obstetric history or prenatal ultrasound.
Pregnancy complications were pre-eclampsia, HELLP,
eclampsia, antepartum haemorrhage (after 20 weeks),
admission to hospital for preterm labour after 20 weeks
and infection if this was an indication for delivery. The
deﬁnition of these conditions was established prior to
data collection. Pre-eclampsia was a speciﬁc item col-
lected in the EPICE study and was deﬁned as protein-
uria and systolic blood pressure ≥140 mm Hg and/or
diastolic blood pressure ≥90 mm Hg occurring after
gestational week 20+0 in a woman who was normoten-
sive prior to becoming pregnant. Proteinuria was
deﬁned as ≥300 mg/L protein in a random specimen or
an excretion of 300 mg/24 hours. Hypertension had
to be conﬁrmed by two separate measurements. HELLP
syndrome was deﬁned as a cluster of laboratory
abnormalities including serum lactic dehydrogenase
>600 U/L, serum aspartate aminotransferase or serum
alanine aminotransferase >70 U/L and platelet count
<100 000/mm3. Eclampsia was deﬁned as the onset of
seizures in a woman with pre-eclampsia.
From the obstetrical unit questionnaire, we used infor-
mation on reported treatment policies and practices
for treatment of preterm labour and for use of MgSO4.
The units were asked if “in your unit, magnesium sul-
fate is used to treat pre-eclampsia or for fetal neuropro-
tection”. Possible responses were ‘whenever possible’,
‘sometimes’ or ‘never’. Information on the ﬁrst-line
tocolytics used in the unit was also collected.
Study population
We deﬁned two populations in order to assess use of
MgSO4 for severe pre-eclampsia or for fetal neuropro-
tection (see ﬁgure 1 for the study ﬂow chart). For both
populations, we excluded women giving birth before 24
+0 weeks of gestation due to expected differences in
levels of treatment for this extremely low gestational age.
We also excluded women who had not received prenatal
steroids. We hypothesised that if there had been time to
administer steroids, MgSO4 could also have been given.
We also excluded all Danish units in the sample as they
were participating in a national, randomised, double-
blinded controlled trial of the use of MgSO4 for fetal
neuroprotection in preterm birth during the study
period. Finally, units with fewer than 20 very preterm
deliveries per year were excluded in order to focus on
units which regularly cared for high-risk pregnancies
and to obtain a sufﬁcient sample size to assess use at the
unit level.
The ﬁrst population included women who had severe
pre-eclampsia. We could not use the commonly accepted
criteria20 for severe pre-eclampsia as information on
blood pressures, urine samples, blood chemistry and
symptoms was not collected. Instead, we deﬁned severe
pre-eclampsia as a diagnosis of eclampsia or HELLP,
regardless of mode of delivery or as a diagnosis of pre-
eclampsia combined with a prelabour caesarean section
performed for maternal indications before 32 weeks of
gestation. We excluded women who had prelabour cae-
sarean sections for fetal indications (eg, IUGR, fetal dis-
tress), due to intrauterine infection or in association
with preterm prelabour rupture of membranes
(PPROM).
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The second population was constituted of women
without a diagnosis of pre-eclampsia, eclampsia or
HELLP; we surmised that in this group, MgSO4 would
be given for indications unrelated to pre-eclampsia, that
is, fetal neuroprotection or tocolysis.
Analysis strategy
We ﬁrst described the characteristics of the two popula-
tions included in our study and then described units’
reported policies for use of MgSO4 as well as the actual
use in these units by indication (the per cent of women
in each relevant population receiving MgSO4 in each
unit). We then explored maternal, pregnancy and
neonatal factors as well as unit policy associated with
MgSO4 use in the cohort, using univariable and multi-
variable analyses. For multivariable analyses, we used
mixed-effect logistic models to take into consideration
the hierarchical structure of our data (correlation
between observations within regions).
In sensitivity analyses, we removed all pre-eclamptic
pregnancies associated with antenatally detected IUGR
to remove situations in which the indicated delivery may
have been for fetal reasons. We also compared our ﬁnal
models including patient and unit variables with a
model including only patient level factors. Finally, we
assessed the impact of excluding units with fewer than
Figure 1 Flow chart—definition of study populations and use of MgSO4. MgSO4, magnesium sulfate; PPROM, preterm
prelabour rupture of membranes.
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20 very preterm births from our study population by
comparing policies in included and excluded units and
the women delivering in these units.
Analyses were carried out using STATA version 13.1 SE
(Stata Corporation, College Station, Texas, USA).
RESULTS
In the EPICE cohort, 4874 women from 119 different units
were considered for the study after exclusions; the ﬁnal
analysis included 4378 women after further exclusions of
cases with pre-eclampsia associated with spontanous onset
of labour, PPROM or cesasrean section for fetal reasons, as
well missing data on MgSO4 (see ﬁgure 1 for the study ﬂow
chart). Of these women, 720 were classiﬁed as having
severe pre-eclampsia, eclampsia or HELLP; 3658 were clas-
siﬁed as not having these conditions. Among women with
severe pre-eclampsia, eclampsia or HELLP, 35.4% received
MgSO4 before delivery (ﬁgure 1). This proportion was
33.7% for pre-eclamptic women without either a diagnosis
of HELLP or eclampsia (data not shown). Among women
without pre-eclampsia, eclampsia or HELLP, only 2.6%
received MgSO4 before delivery.
Table 1 describes the study populations. As expected,
the maternal and pregnancy characteristics of the pre-
eclamptic and non-pre-eclamptic women differed.
Women with severe pre-eclampsia were slightly more
likely to have both lower and higher ages and were more
often primiparous. They also had lower rates of deliver-
ies at extremely preterm gestations (<26 weeks of gesta-
tion). The proportion of female infants was higher in
the pre-eclamptic population than in the
non-pre-eclamptic population (54.2% and 45.2%,
respectively). The proportion of multiple pregnancies
was lower in the pre-eclamptic population than in the
non-pre-eclamptic population. IUGR was diagnosed
before birth in 41.3% of the cases in the pre-eclamptic
population, and in 12.8% of the cases in the
non-pre-eclamptic population. The number of in utero
transfers in the two populations was similar, but the rates
of caesarean sections were much higher in the pre-
eclamptic population (99.2% and 60.4%, respectively).
Table 2 shows the policies as well as the actual use of
MgSO4 in European obstetrical units. For severe pre-
eclampsia, eclampsia or HELLP, most units reported
using MgSO4 whenever possible (41.2%) or sometimes
(41.2%). Practices reﬂected policies. Units reporting use
of MgSO4 whenever possible had higher median rates of
MgSO4 use than units reporting a policy of MgSO4 use
sometimes (25.0% vs 12.5%). However, many units did
not use MgSO4 over the study period (as seen by the
IQR) despite a reported policy treatment. Only 5 of
119 units said that they did not use MgSO4 for severe
pre-eclampsia, eclampsia or HELLP and this was consist-
ent with observed rates of use. Ten units did not
respond to the question of MgSO4 treatment for severe
pre-eclampsia, eclampsia or HELLP and 6 units did not
return the questionnaire; in these 16 units, MgSO4 was
used over the study period.
For fetal neuroprotection, very few units reported
using MgSO4 whenever possible (7.6%); a further 16.0%
reported a policy of MgSO4 treatment sometimes.
Observed rates varied by unit responses, but rates were
low even in units that had a policy of MgSO4 treatment
‘whenever possible’; the median rate of MgSO4 treat-
ment of women in the non-pre-eclamptic population
was 14.3%.
Only 1 unit (<1%) with a small number of women in
the study population reported using MgSO4 as a ﬁrst-line
tocolytic.
Table 3 provides data on policies and observed use of
MgSO4 when regions are grouped by country. There was
a large variability in both unit policies and actual use
among women (online supplementary table S1 provides
information on the study population and the exclusion
criteria as applied to each country). Some countries
appeared to use MgSO4 routinely for severe pre-
eclampsia, eclampsia or HELLP, whereas use was much
lower in others (France, Italy and Portugal). Use in the
non-pre-eclamptic population was low in all study
regions, and in 6 of 10 countries, fewer than 3% of
women in the non-pre-eclamptic population were
treated with MgSO4.
Table 4 shows the factors associated with greater use of
MgSO4 in the pre-eclamptic and the non-pre-eclamptic
population. For women in the pre-eclamptic population,
a gestational age between 26+0–28+6 weeks and/or
having a diagnosis of eclampsia was associated with more
frequent use of MgSO4. In the same population, having a
diagnosis of IUGR or HELLP and admission for preterm
labour were associated with less frequent use of MgSO4.
While the proportion of women receiving MgSO4 was
higher in units reporting use whenever possible, the dif-
ference was not signiﬁcant in adjusted analyses. In the
non-pre-eclamptic population, gestational ages from 24
+0–25+6 to 26+0–28+6 were associated with more fre-
quent use of MgSO4, whereas lack of a unit policy on the
use of MgSO4 was associated with less frequent use. In
the non-pre-eclamptic group, being hospitalised for
preterm labour was not associated with use of MgSO4.
Sensitivity analyses showed similar results in the pre-
eclamptic group when cases with antenatal detection of
IUGR were removed (see online supplementary table
S2) and individual patient level characteristics had a
similar impact in models without unit policy variables
(see online supplementary table S3). Policies and prac-
tices in the 10 units in the unit study that were excluded
because they had fewer than 20 very preterm births per
year were not signiﬁcantly different from units included
in our study (see online supplementary table S4).
DISCUSSION
Main findings
This large, population-based observational study yielded
three main ﬁndings on the use of MgSO4 for very
preterm birth in European obstetric units. First, we
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found that severe pre-eclampsia, eclampsia and HELLP
were treated with MgSO4, but not as frequently as
evidence-based medicine recommends. Second, we
found that MgSO4 was seldom used for fetal neuropro-
tection, and third, that MgSO4 is no longer used for
tocolysis.
Strengths and limitations
The strengths of the study are its multinational, pro-
spective population-based sample which includes deliver-
ies in all public and private maternity hospitals in 19
regions in 11 European countries covering over 850 000
births annually. Also, both tertiary and non-tertiary
centres were included. This ensures high generalisability
to a wide range of settings. The risk of interobserver
variability between units was minimised by using pre-
established deﬁnitions of diagnoses and terms and pre-
testing questionnaires in all regions.
Limitations include some missing data on administra-
tion of MgSO4. We also did not have indications for
MgSO4 use and therefore created subgroups of patients
likely to receive MgSO4 for severe pre-eclampsia or neu-
roprotection. In the group of women without pre-
eclampsia, we assumed that MgSO4 was given either for
neuroprotection or tocolysis. For women with pre-
eclampsia, we could not validate the diagnosis of severe
pre-eclampsia as blood pressures, urine samples and
blood chemistry were not collected, but we assumed that
a pre-eclamptic condition resulting in a prelabour cae-
sarean section on maternal indication before 32 weeks
of gestation was most likely to be severe. While we
excluded prelabour caesareans for fetal indications and
intrauterine infection in order to remove women
unlikely to have severe pre-eclampsia, some caesareans
could have been carried out primarily for IUGR, even if
maternal reasons were also indicated. To address this
Table 1 Description of women delivering between 24+0 and 31+6 weeks of gestation with severe pre-eclampsia, eclampsia
or HELLP (population 1) and without a diagnosis of pre-eclampsia, HELLP or eclampsia (population 2)
Women with severe
pre-eclampsia* (n=720)
Women without pre-eclampsia,
HELLP or eclampsia (n=3658) p Value
n (%) n (%)
Maternal age (years)
<25 138 (19.3) 631 (17.3) 0.037
25–34 364 (50.8) 2044 (56.0)
≥35 214 (29.9) 972 (26.7)
Parity
Primiparous 474 (66.2) 1944 (53.5) <0.001
Multiparous 242 (33.8) 1690 (46.5)
Gestational age (weeks)
24+0–25+6 48 (6.7) 453 (12.4) <0.001
26+0–28+6 216 (30.0) 1148 (31.4)
29+0–31+6 456 (63.3) 2057 (56.2)
Diagnosis of IUGR
No 421 (58.7) 3173 (87.2) <0.001
Yes 296 (41.3) 466 (12.8)
Sex of baby
Male 329 (45.8) 2006 (54.8) <0.001
Female 390 (54.2) 1652 (45.2)
Type of pregnancy
Singleton 682 (94.7) 2846 (77.8) <0.001
Multiple 38 (5.3) 811 (22.2)
Pregnancy complications
Eclampsia 51 (7.2) –
HELLP 198 (27.8) –
Antepartum haemorrhage 26 (3.7) 865 (23.9) <0.001
Admission for preterm labour 35 (4.9) 1974 (54.4) <0.001
PPROM – 1283 (35.2) <0.001
Infection as indication for delivery – 421 (12.2) <0.001
In utero transfer 249 (35.0) 1242 (34.2) 0.668
Mode of delivery
Vaginal 6 (0.8) 1441 (39.6) <0.001
Caesarean 709 (99.2) 2195 (60.4)
*Defined as a diagnosis of eclampsia or HELLP, regardless of mode of delivery or a diagnosis of pre-eclampsia and a prelabour caesarean
section.
HELLP, Haemolysis, elevated liver enzymes, low platelets; IUGR, intrauterine growth restriction; PPROM, preterm prelabour rupture of
membranes.
Wolf HT, et al. BMJ Open 2017;7:e013952. doi:10.1136/bmjopen-2016-013952 5
Open Access
group.bmj.com on February 26, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
issue, we carried out a sensitivity analysis removing these
cases and our results were similar.
Interpretation
Despite global consensus about its effectiveness and
safety for preventing eclampsia, only 41.2% of the units
reported use of MgSO4 whenever possible in case of pre-
eclampsia and MgSO4 was used in only 35.4% of women
with severe pre-eclampsia, eclampsia or HELLP. This
might be a slight underestimation as only antenatal use
was registered. A Canadian study from 2015 found a dis-
crepancy between national and local guidelines.17 In the
Canadian study, 79% of women with severe pre-
eclampsia received MgSO4. However, this estimate was
based on only 174 patients and suffered from variation
in the deﬁnition of severe pre-eclampsia. We found wide
country variation in use of MgSO4, with lower use in
France, Italy and Portugal. While studies on practices of
MgSO4 use in European countries are lacking, several
studies have examined MgSO4 administration for
women with eclampsia and have documented low use
for prevention in these cases.21–23
Our results are also in line with evidence from Mexico
and Thailand showing that MgSO4 is underused in
women with pre-eclampsia and eclampsia.24 Multiple
barriers have been identiﬁed in low-income and
middle-income countries, including failure in registra-
tion, distribution, unmet training needs, suboptimal
implementation of guidelines and reluctance of staff to
use MgSO4 because of required intensive patient moni-
toring.24–27 High-income countries have fewer barriers
for accessing antenatal care, early diagnosis of pre-
eclampsia and follow-up during and after delivery.
However, the same challenges may exist with respect to
medical staff concerns about the handling of MgSO4
and risks of serious maternal side effects, such as respira-
tory arrest, arrhythmia and pulmonary oedema.
The evidence that MgSO4 is an ineffective tocolytic
appears to be integrated into clinical practice. Only
1 unit reported using MgSO4 as a ﬁrst-line tocolytic and
use was not higher among women admitted to hospital
for preterm labour in the non-pre-eclamptic population.
Despite the Cochrane meta-analysis published in
2009,5 an ACOG guideline from March 201028 and an
RCOG scientiﬁc impact statement in August 201129 all
recommending use of MgSO4 for fetal neuroprotec-
tion, this study reveals an almost non-existing use of
MgSO4 for fetal neuroprotection in Europe in the
study period. The reluctance to adopt this practice may
be due to the trial sequential analysis from 2011 con-
cluding that randomisation of an additional 400
women was needed to obtain sufﬁcient evidence to
introduce MgSO4 as a standard treatment for neuro-
protection.7 Other possible explanations are the fairly
high number-needed-to-treat of 56 (95% CI 26 to 187)
to prevent cases of cerebral palsy in deliveries before
34 weeks of gestation,30 lack of clinical guidelines, and
concerns for adverse drug effects necessitating intense
monitoring when administering MgSO4. Finally, some
obstetricians might be waiting for the results of an
ongoing randomised controlled trial from Denmark
expected in 2018.31
Since our study, new guidelines for neuroprotection
were issued in two of the countries participating in
EPICE, the UK in November 201514 and Belgium in July
2014.16 Guidelines were also issued in Ireland, which is
not part of EPICE.15 In both guidelines, MgSO4 is highly
recommended for neuroprotection to women present-
ing with imminent preterm birth before 32 weeks of ges-
tation. It is therefore possible that practices have evolved
Table 2 Policies and observed use of MgSO4 for severe pre-eclampsia, eclampsia or HELLP, for fetal neuroprotection or for
tocolysis in women delivering very preterm (<32 weeks of gestation) in European obstetrical units
Maternity
units
(n=119)
Women with
severe
pre-eclampsia
(n=720)
Percentage of
pre-eclamptic
women receiving
MgSO4 in units
Women without
pre-eclampsia,
eclampsia or
HELLP (n=3658)
Percentage of
non-pre-eclamptic
women receiving
MgSO4 in units
n (%) n (%) Median (IQR) n (%) Median (IQR)
Unit policy for pre-eclampsia
MgSO4 whenever possible 49 (41.2) 296 (41.1) 25.0 (0–60.0) 1623 (44.4) 0 (0–3.0)
MgSO4 sometimes 49 (41.2) 339 (47.1) 12.5 (0–42.9) 1554 (42.5) 0 (0–0)
Never 5 (4.2) 32 (4.4) 0 (0–0) 145 (4.0) 0 (0–0)
No response* 16 (13.4) 53 (7.4) 34.8 (0–60.0) 336 (9.2) 0 (0–1.4)
Unit policy for neuroprotection
MgSO4 whenever possible 9 (7.6) 69 (9.6) 33.3 (16.7–72.7) 260 (7.1) 14.3 (0–37.8)
MgSO4 sometimes 19 (16.0) 118 (16.4) 20.0 (0–60.0) 749 (20.5) 0 (0–4.8)
Never 70 (58.8) 454 (63.1) 11.8 (0–50.0) 2173 (59.4) 0 (0–0)
No response† 21 (17.6) 79 (11.0) 36.4 (0–60.0) 476 (13.0) 0 (0–1.9)
MgSO4 is a first-line tocolytic 1 (0.88) 0 (0.0) 0.0 8 (0.2) 0.0
*Includes 10 units that returned the questionnaire, but did not respond to this question and six units that did not return the unit questionnaire.
†Includes 15 units that returned the questionnaire, but did not respond to this question and six units that did not return the unit questionnaire.
MgSO4, magnesium sulfate.
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Table 3 Policies and observed use of MgSO4 treatment for very preterm birth (<32 weeks of gestation) by indication and country
Country (region) Units
Whenever possible
for pre-eclampsia
Women with
severe
pre-eclampsia
Women
receiving
MgSO4
Whenever possible or
sometimes for
neuroprotection
Women without
pre-eclampsia, HELLP
or eclampsia
Women
receiving
MgSO4
n Percentage of units n Per cent Percentage of units n Per cent
Belgium (Flanders) 9 33.3 70 67.1 11.1 367 2.7
Estonia (whole country) 3 33.3 19 21.1 0.0 93 3.2
France (Northern region,
Burgundy, Ile-de-France)
21 0.0 155 18.1 23.8 550 2.0
Germany (Hesse,
Saarland)
13 53.9 45 40.0 30.8 228 6.6
Italy (Lazio,
Emilia-Romania, Marche)
20 50.0 107 15.9 25.0 620 1.1
Netherlands
(East-Central)
2 50.0 45 91.1 50.0 206 0.5
Poland (Wielkopolska) 2 100.0 5 60.0 100.0 114 12.3
Portugal (Northern and
Lisbon)
13 76.9 88 9.1 38.5 399 5.5
Sweden (Stockholm) 4 0.0 40 40.0 0.0 147 0.0
UK (Northern, East
Midlands, Yorkshire &
Humber)
32 46.9 146 50.0 15.6 934 1.3
Women with a non-anomalous live birth who received prenatal corticosteroids and delivered in a maternity unit with more than 20 very preterm deliveries annually (see online supplementary
table S1 for exclusions by country).
MgSO4, magnesium sulfate.
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Table 4 Maternal and unit factors associated with MgSO4 treatment of women with severe pre-eclampsia, eclampsia or HELLP or fetal neuroprotection in women without
pre-eclampsia, eclampsia or HELLP
Women with severe pre-eclampsia* (255/720) Women without pre-eclampsia, HELLP or eclampsia (95/3658)
Receiving MgSO4 n/N Per cent aOR 95% CI n/N Per cent aOR 95% CI
Maternal age (years)
<25 58/158 42.0 1.32 (0.72 to 2.41) 24/631 3.8 1.68 (0.84 to 3.35)
25–34 131/364 36.0 0.89 (0.56 to 1.42) 47/2044 2.3 0.86 (0.48 to 1.55)
≥35 64/214 29.9 Ref. 24/972 2.5 Ref.
Parity
Primiparous 77/242 31.8 1.07 (0.7 to 1.65) 44/1690 2.6 0.84 (0.51 to 1.36)
Multiparous 177/474 37.3 Ref. 50/1944 2.6 Ref.
Gestational age (weeks)
24+0–25+6 18/48 37.5 1.71 (0.78 to 3.74) 18/453 4.0 2.31 (1.13 to 4.74)
26+0–28+6 86/216 39.8 1.64 (1.07 to 2.51) 36/1148 3.1 1.71 (1.02 to 2.86)
29+0–31+6 151/456 33.1 Ref. 41/2057 2.0 Ref.
Diagnosis of IUGR
No 161/421 38.2 Ref. 79/3173 2.5 Ref.
Yes 92/296 31.1 0.65 (0.43 to 0.99) 14/466 3.0 1.12 (0.54 to 2.33)
Sex of baby
Male 112/329 34.0 0.89 (0.6 to 1.32) 54/2006 2.7 0.90 (0.55 to 1.45)
Female 143/390 36.7 Ref. 41/1652 2.5 Ref.
Type of pregnancy
Singleton 13/38 34.2 1.19 (0.47 to 3.03) 12/811 1.5 1.80 (0.92 to 3.54)
Multiple 242/682 35.5 Ref. 83/2846 2.9 Ref.
Pregnancy complications
Eclampsia 23/51 45.1 2.21 (1.03 to 4.71) – – – –
HELLP 72/198 36.4 0.60 (0.37 to 0.97) – – – –
Antepartum haemorrhage 7/26 26.9 0.49 (0.15 to 1.56) 23/865 2.7 0.78 (0.44 to 1.41)
Admission for preterm labour 4/35 11.4 0.18 (0.04 to 0.7) 51/1974 2.6 0.67 (0.39 to 1.15)
PPROM 1/5 – – – 29/1283 2.3 0.57 (0.32 to 1.01)
Infection as indication for delivery 1/1 100 – – 14/421 3.3 1.30 (0.64 to 2.64)
In utero transfer 95/295 38.2 1.44 (0.92 to 2.27) 34/1242 2.7 0.78 (0.45 to 1.36)
Unit polices of MgSO4 use
for pre-eclampsia
Whenever possible 125/296 42.2 Ref. – – – –
Sometimes 106/339 31.3 0.73 (0.43 to 1.25) – – – –
Never 0/32 0.0 – – – – – –
No response 29/53 45.3 0.70 (0.34 to 1.47) – – – –
for neuroprotection
Whenever possible – – – – 47/260 18.1 Ref.
Sometimes – – – – 24/749 3.2 0.08 (0.03 to 0.19)
Never – – – – 14/2173 0.6 0.02 (0.01 to 0.04)
No response – – – – 10/476 2.1 0.08 (0.03 to 0.24)
*Defined as a diagnosis of eclampsia or HELLP, regardless of mode of delivery, or a diagnosis of pre-eclampsia and a prelabour caesarean section before 32 weeks of gestation.
HELLP, Haemolysis, elevated liver enzymes, low platelet count; IUGR, intrauterine growth restriction; PPROM, preterm prelabour rupture of membranes.
MgSO4, magnesium sulfate.
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in these countries. To the best of our knowledge,
however, there have been no new guidelines in other
regions and no new evidence from randomised trials of
the effectiveness of MgSO4 has been published.
CONCLUSION
Evidence-based use of MgSO4 is applied less than
expected in European obstetric units. Future research
should focus on how to promote evidence-based use of
MgSO4 for severe pre-eclampsia. Options include an
increased focus on the existing guidelines, instituting
audits and simulation training in the maternity ward to
familiarise medical staff with the handling of MgSO4.
Our results showing low use of MgSO4 in
non-pre-eclamptic women suggest that obstetricians are
not convinced by available evidence on MgSO4’s neuro-
protective effect. Our results provide a useful baseline
for evaluating practice changes as more evidence
becomes available and more national societies develop
guidelines for use of MgSO4 for neuroprotection.
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(I level); Szpital Powiatowy im. Jana Pawła II w Trzciance (I level);
Samodzielny Publiczny Zakład Opieki Zdrowotnej w Turku (I level); Zespół
Opieki Zdrowotnej w Wag̨rowcu (I level); Samodzielny Publiczny Zakład Opieki
Zdrowotnej w Wolsztynie (I level); Szpital Powiatowy we Wrzesni (I level);
Szpital Powiatowy w Wyrzysku (I level); Szpital Powiatowy
im. A. Sokołowskiego w Złotowie (I level). Portugal (Northern Region); Centro
Hospitalar de Entre o Douro e Vouga, E.P.E.—Hospital de São Sebastião;
Centro Hospitalar de Trás-os-Montes e Alto Douro, E.P.E.—Hospital São
Pedro; Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.—Unidade II;
Centro Hospitalar do Alto Ave, E.P.E.—Unidade de Guimarães; Centro
Hospitalar do Médio Ave, E.P.E.—Unidade de Famalicão; Centro Hospitalar do
Porto, E.P.E.—Maternidade Júlio Dinis; Centro Hospitalar do Tâmega e
Sousa, E.P.E.—Hospital Padre Américo; Centro Hospitalar Póvoa de Varzim—
Vila do Conde, E.P.E.—Unidade da Póvoa de Varzim; Centro Hospitalar São
João, E.P.E.—Hospital São João; Hospital de Braga; Unidade Local de Saúde
de Matosinhos, E.P.E.—Hospital Pedro Hispano; Unidade Local de Saúde do
10 Wolf HT, et al. BMJ Open 2017;7:e013952. doi:10.1136/bmjopen-2016-013952
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Alto Minho, E.P.E.—Hospital de Santa Luzia; Unidade Local de Saúde do
Nordeste, E.P.E.—Unidade de Bragança. Portugal (Lisbon and Tagus Valley
Region) : Centro Hospitalar Barreiro Montijo, E.P.E.- Hospital Nossa Senhora
do Rosário; Centro Hospitalar de Lisboa Central, E.P.E.—Hospital Dona
Estefânia; Centro Hospitalar de Lisboa Central, E.P.E.—Maternidade Alfredo da
Costa; Centro Hospitalar de Lisboa Ocidental, E.P.E.—Hospital de São
Francisco Xavier; Centro Hospitalar de Setúbal, E.P.E.—Hospital São
Bernardo; Centro Hospitalar do Médio Tejo, E.P.E.—Hospital Doutor Manoel
Constâncio; Centro Hospitalar do Oeste—Unidade de Caldas da Rainha;
Centro Hospitalar do Oeste—Unidade de Torres Vedras; Centro Hospitalar
Lisboa Norte, E.P.E.—Hospital Santa Maria; Hospital Cuf Descobertas;
Hospital da Luz; Hospital de Cascais Dr. José de Almeida; Hospital de
Santarém, E.P.E.; Hospital Garcia de Orta, E.P.E.; Hospital Lusíadas Lisboa;
Hospital Professor Doutor Fernando Fonseca, E.P.E.; Hospital Vila Franca de
Xira. Sweden (Stockholm): Department of Obstetrics and Gynecology,
Danderyd Hospital, Stockholm; BB Stockholm AB, Danderyd Hospital,
Stockholm; Department of Obstetrics and Gynecology, Karolinska University
Hospital (units in Solna and Huddinge), Stockholm; Department of Obstetrics
and Gynecology, Sodersjukhuset (Stockholm South General Hospital),
Stockholm; Department of Obstetrics and Gynecology, Sodertalje Hospital;
Department of Neonatal Medicine, Karolinska University Hospital (units in
Danderyd, Solna and Huddinge), Stockholm; Sachs’ Children and Youth
Hospital, Stockholm. UK (Northern Region): Royal Victoria Infirmary
Newcastle on Tyne; James Cook University Hospital Middlesbrough; North
Tees University Hospital Stockton; Sunderland Royal Hospital; Wansbeck
Hospital Ashington; Queen Elizabeth Hospital Gateshead; North Tyneside
General Hospital; South Tyneside General Hospital; Cumberland Infirmary
Carlisle; West Cumberland Infirmary. UK (East Midlands—Yorkshire &
Humber): Chesterfield Royal Hospital;Bassetlaw District General Hospital;Kings
Mill Hospital;Royal Derby Hospital;Nottingham City Hospital;Nottingham
Queen’s Medical Centre;Lincoln County Hospital;Boston Pilgrim Hospital;
University Hospitals of Leicester (LGH + LRI);Kettering General Hospital;
Northampton General Hospital;Grimsby Diana Princess of Wales Hospital;
Scunthorpe General Hospital;Barnsley District General Hospital;Rotherham
District General Hospital;Doncaster Royal Infirmary;Jessop Wing Sheffield;
Airedale District General Hospital;Bradford Royal Infirmary;Dewsbury District
General Hospital;Halifax Calderdale Royal Infirmary;Harrogate District General
Hospital;Hull Royal Infirmary;Leeds General Infirmary; Leeds St James’s;
Scarborough District General Hospital;York District Hospital;Wakefield
Pinderfields General Hospital.
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